12. March 2016

Evonik has developed a formulation technology, which offers a novel approach to developing alcohol resistant oral drug products with delayed or sustained release profiles. EUDRATEC™ ADD delivers a solution to the problem of alcohol-induced dose dumping of modified release dosage forms and enables the pharmaceutical industry to be in accordance with the sharpened requirements of the US-FDA. If patients take oral drugs, designed with a modified release (MR) profile, together with alcohol, the...